Elexacaftor/tezacaftor/ivacaftor

# Elexacaftor/Tezacaftor/Ivacaftor (Trikafta/Kaftrio)

---

Who / What

**Elexacaftor/tezacaftor/ivacaftor**, sold under the brand names **Trikafta** and **Kaftrio**, is a fixed-dose combination medication designed to treat cystic fibrosis. It comprises three active ingredients: elexacaftor and tezacaftor (CFTR modulators) and ivacaftor (a chloride channel opener), working together to improve CFTR protein function in patients with specific genetic mutations.

---

Background & History

Developed through collaborative efforts between pharmaceutical companies, **Elexacaftor/tezacaftor/ivacaftor** emerged as a breakthrough treatment for cystic fibrosis. The drug was initially approved based on clinical trials demonstrating its efficacy in enhancing lung function and reducing exacerbations in patients carrying the F508del mutation or other CFTR gene mutations. Key milestones include FDA approval in 2019 (for Trikafta) and subsequent global expansion, marking a significant advancement in managing cystic fibrosis.

---

Why Notable

This medication represents one of the most transformative treatments for cystic fibrosis to date, offering hope to patients by improving quality of life, reducing hospitalizations, and extending survival. Its success has redefined therapeutic approaches for genetic disorders, setting new standards for precision medicine and drug development in rare diseases.

---

In the News

As a groundbreaking cystic fibrosis treatment, **Elexacaftor/tezacaftor/ivacaftor** remains highly relevant due to its widespread adoption globally. Recent developments include expanded access programs, ongoing research into long-term efficacy, and discussions about cost-effectiveness and affordability in healthcare systems.

---

Key Facts

**Type**: Medical drug (pharmaceutical combination)

**Also known as**:

Trikafta (when sold alone)

Kaftrio (combination with other CFTR modulators)

**Key dates**:

FDA approval for cystic fibrosis: December 2019 (Trikafta)

First commercial availability in the U.S.: Early 2020

**Geography**: Primarily marketed in the United States, Europe, and other regions with cystic fibrosis patient populations.

**Affiliation**:

Developed by Vertex Pharmaceuticals and Pfizer (now part of a joint venture).

Targets patients with cystic fibrosis caused by specific CFTR gene mutations.

---

Links

[Wikipedia](https://en.wikipedia.org/wiki/Elexacaftor%2Ftezacaftor%2Fivacaftor)

Sources

• 🔗 Wikipedia

Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. The combination is approved for medical use in the United States for people aged two years of age and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene.